These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17177422)

  • 1. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.
    Lawhorn BG; Boga SB; Wolkenberg SE; Colby DA; Gauss CM; Swingle MR; Amable L; Honkanen RE; Boger DL
    J Am Chem Soc; 2006 Dec; 128(51):16720-32. PubMed ID: 17177422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
    Swingle MR; Amable L; Lawhorn BG; Buck SB; Burke CP; Ratti P; Fischer KL; Boger DL; Honkanen RE
    J Pharmacol Exp Ther; 2009 Oct; 331(1):45-53. PubMed ID: 19592665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues.
    Bialy L; Waldmann H
    Chemistry; 2004 Jun; 10(11):2759-80. PubMed ID: 15195307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fostriecin: chemistry and biology.
    Lewy DS; Gauss CM; Soenen DR; Boger DL
    Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition.
    Buck SB; Hardouin C; Ichikawa S; Soenen DR; Gauss CM; Hwang I; Swingle MR; Bonness KM; Honkanen RE; Boger DL
    J Am Chem Soc; 2003 Dec; 125(51):15694-5. PubMed ID: 14677930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A.
    Kawada M; Amemiya M; Ishizuka M; Takeuchi T
    Biochim Biophys Acta; 1999 Nov; 1452(2):209-17. PubMed ID: 10559474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of cytostatin analogues.
    Bialy L; Waldmann H
    Chem Commun (Camb); 2003 Aug; (15):1872-3. PubMed ID: 12932009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total synthesis and evaluation of phostriecin and key structural analogues.
    Burke CP; Swingle MR; Honkanen RE; Boger DL
    J Org Chem; 2010 Nov; 75(22):7505-13. PubMed ID: 20669916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asymmetric total synthesis of (+)-fostriecin.
    Reddy YK; Falck JR
    Org Lett; 2002 Mar; 4(6):969-71. PubMed ID: 11893198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potent protein phosphatase 2A inhibitors aminocytostatins: new derivatives of cytostatin.
    Tohyama S; Kawada M; Muramatsu H; Hatano M; Inoue H; Matoba K; Sawa R; Igarashi M
    J Antibiot (Tokyo); 2021 Oct; 74(10):743-751. PubMed ID: 34290381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total synthesis, assignment of the relative and absolute stereochemistry, and structural reassignment of phostriecin (aka Sultriecin).
    Burke CP; Haq N; Boger DL
    J Am Chem Soc; 2010 Feb; 132(7):2157-9. PubMed ID: 20108904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Versatile enantiocontrolled synthesis of (+)-fostriecin.
    Esumi T; Okamoto N; Hatakeyama S
    Chem Commun (Camb); 2002 Dec; (24):3042-3. PubMed ID: 12536807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalyst-controlled asymmetric synthesis of fostriecin and 8-epi-fostriecin.
    Maki K; Motoki R; Fujii K; Kanai M; Kobayashi T; Tamura S; Shibasaki M
    J Am Chem Soc; 2005 Dec; 127(48):17111-7. PubMed ID: 16316259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A.
    Walsh AH; Cheng A; Honkanen RE
    FEBS Lett; 1997 Oct; 416(3):230-4. PubMed ID: 9373158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of Dehydro-Dephospho-Fostriecin and Formal Total Synthesis of Fostriecin.
    Gao D; Li B; O'Doherty GA
    Org Lett; 2019 Oct; 21(20):8334-8338. PubMed ID: 31584287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of the protein phosphatase 2A inhibitor (4S,5S,6S,10S,11S,12S)-cytostatin.
    Bialy L; Waldmann H
    Angew Chem Int Ed Engl; 2002 May; 41(10):1748-51. PubMed ID: 19750704
    [No Abstract]   [Full Text] [Related]  

  • 17. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia.
    Weinbrenner C; Baines CP; Liu GS; Armstrong SC; Ganote CE; Walsh AH; Honkanen RE; Cohen MV; Downey JM
    Circulation; 1998 Sep; 98(9):899-905. PubMed ID: 9738645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
    Kawada M; Kawatsu M; Masuda T; Ohba S; Amemiya M; Kohama T; Ishizuka M; Takeuchi T
    Int Immunopharmacol; 2003 Feb; 3(2):179-88. PubMed ID: 12586599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total synthesis of fostriecin: via a regio- and stereoselective polyene hydration, oxidation, and hydroboration sequence.
    Gao D; O'Doherty GA
    Org Lett; 2010 Sep; 12(17):3752-5. PubMed ID: 20687585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total synthesis of an antitumor antibiotic, Fostriecin (CI-920).
    Miyashita K; Ikejiri M; Kawasaki H; Maemura S; Imanishi T
    J Am Chem Soc; 2003 Jul; 125(27):8238-43. PubMed ID: 12837094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.